EICHORCondition: Multiple Myeloma · Sponsor: Oncotherapeutics
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM). Pomalidomide (alone or in combination with dexamethasone) has been approved by the United States Food and Drug Administration (FDA) for the treatment of MM patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of their last therapy. However, the use of pomalidomide in combination with other drugs used to treat MM, such as chemotherapeutic agents and proteasome inhibitors, is currently being tested and is not approved. Pomalidomide is in the same drug class as thalidomide and lenalidomide. Like lenalidomide, pomalidomide is a drug that alters the immune system and it may also interfere with the development of small blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. The testing done with pomalidomide thus far has shown that it is well-tolerated and effective for subjects with MM both on its own and in combination with dexamethasone. Using another drug class, namely proteasome inhibitors, we have demonstrated that simply replacing a …
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| California Cancer Associates for Research & Excellence (cCARE) | Encinitas, California, United States | — |
| Compassionate Care Research Group | Fountain Valley, California, United States | — |
| Comprehensive Cancer Center at Desert Regional Medical Center | Palm Springs, California, United States | — |
| Inland Hematology Oncology Medical Group, Inc | San Bernardino, California, United States | — |
| Wellness Oncology and Hematology | West Hills, California, United States | — |
| James R. Berenson, MD, Inc. | West Hollywood, California, United States | — |
| VA Sierra Nevada | Reno, Nevada, United States | — |
| San Juan Oncology Associates | Farmington, New Mexico, United States | — |
| Gabrail Cancer Center | Canton, Ohio, United States | — |
| Rapid City Regional Hospital | Rapid City, South Dakota, United States | — |
| Wellmont Medical Associates Oncology and Hematology | Kingsport, Tennessee, United States | — |
| Vista Oncology | Olympia, Washington, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02188368